Skip to content
naulon
Not checkedNot checked for notices yet.

Impact of process validation and equipment qualification in production of bio-therapeutics

Goutam Ghosh, Rabi Prasad Bodroth, Basabjit Dutta

Journal of Advanced Biotechnology and Experimental Therapeutics · 2022

doi:10.5455/jabet.2022.d105 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Production of therapeutic proteins like Biosimilars uses a complex cell based fermentation and purification process. There are chances of errors in these complex production processes due to complexities in the molecular pathway that every protein follows. Therefore to produce a desired therapeutic protein that elicit the correct immunological response in the patient, one need to ensure that it must have correct sequence, size, structure so that they are recognized by the specific receptors. The quality of these therapeutic proteins are characterized through standard assays and methods such as SDS PAGE (sodium dodecyl sulphatepolyacrylamide gel electrophoresis), IEF (Isoelectric Focusing), Western Blot and other methods those are based on HPLC, Mass Spectrometry and Capillary Electrophoresis to conform the desired molecular size, purity and identity of proteins. Thus in the process of validation of a method, equipment plays a critical role in ensuring the quality and safety of a biopharmaceutical product. It is always necessary to generate scientific data and information such as IQ (Installation Qualification), OQ (Operational Qualification) and PQ (Performance Qualification) protocol and reports for each instrument employed in the process at the beginning and before the actual testing of the desired product. It is only after the completion of these activities, the product under different manufacturing steps can be characterized. Involvement of a software in conjunction to an equipment is also common and it is important that the software is in use with the equipment also meets the requirements of the CFR 21 FDA (Code of Federal Regulations, 21 Part 11 of US Food and Drug Administration), which is a legal requirement in a modern manufacturing process and hence it is important to comply with these rules as set of guidelines that will help ensure the integrity and safety of data. [ J Adv Biotechnol Exp Ther 2022; 5(1.000): 163-175]

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.